Practical Neurology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Practical Neurology 2006;6:208-217; doi:10.1136/jnnp.2006.097709
Copyright © 2006 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pritchard, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pritchard, J.

Reviews

What’s new in Guillain-Barré syndrome?

Jane Pritchard

Correspondence to:
Correspondence to:
Dr Jane Pritchard, Neurology Specialist Registrar, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK;
jpritchard@doctors.org.uk

The first 150 words of the full text of this article appear below.


Figure 4

Guillain-Barré syndrome (GBS) has become the major cause of acute neuromuscular paralysis in the Western world since the eradicationof polio, with an annual incidence of 1–2 per 100,000. It can affect all ages including children, but becomes increasingly common with age. In the 90 years since the syndrome was first described in World War I soldiers, much progress has been made in understanding its aetiology and treatment. Recently a great deal has changed as we increasingly realise that GBS comprises a group of heterogeneous disorders with likely different immunological pathogeneses.

Clinically, it is useful to divide the syndrome into subtypes rather than lump it all together as one disorder. This leads to appropriate use of investigations, informs evidence based management, and provides a more accurate prognosis for patients.

DIAGNOSING GBS

Despite major advances, GBS, like many other neurological diseases, remains a clinical diagnosis. Laboratory tests help support the diagnosis and exclude other . . . [Full text of this article]




This article has been cited by other articles:


Home page
PNHome page
M. Connor
Immune or not immune: two cases of acute flaccid motor paralysis
Practical Neurology, November 1, 2007; 7(6): 412 - 415.
[Full Text] [PDF]


Home page
PNHome page
A. Chancellor
Areflexia as a sine qua non for Guillain-Barre syndrome: very practical neurology
Practical Neurology, December 1, 2006; 6(6): 396 - 396.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd.